Please assess the completion status of the following clinical trial:

Trial Title: Study of the Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Moderately to Severely Active Psoriatic Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Moderate to severe PsA~* Inadequate response to DMARD therapy~* Corticosteroid stable dose \<= 10 mg QD~* DMARDs must have been taken for 3 months and stable dose for 4 weeks~* MTX maximum dose = \<= 30 mg/week~* Active chronic plaque PS or documented history of chronic plaque PS~Exclusion Criteria:~* No other active skin disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: ACTIVE_COMPARATOR): None
- B (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).